MedPath

Ayurveda product clinical trial on overweight subjects

Phase 3
Completed
Registration Number
CTRI/2020/09/027807
Lead Sponsor
IndusViva HealthSciences Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
70
Inclusion Criteria

1.Adult male and non-pregnant females aged 18 to 55 years

2.BMI � 25 kg/m2 to 40 kg/m2 with one or more of the metabolic risk factors (waist circumference �80 cm, fasting glucose �100 mg/dL, BP

�130/85 mmHg, HDL-cholesterol <50 mg/dL OR controlled diabetes, hypertension, dyslipidemia with medications)

3.Able to comply with all required study procedures and schedule.

4.Able to comply and willing to follow the prescribed diet plan.

5.Willing and able to give written informed consent.

6.Subjects who agree to stop from using supplements during the study duration time

7.Subjects willing to refrain from any obesity treatment

8.Subjects willing to follow the suggested diet plan

Exclusion Criteria

1. Participantswithuncontrolledhypertension(systolicblood pressure (SBP) >180 mmHg, or diastolic blood pressure (DBP) >120 mmHg)

2. Participants with hepatic disease (aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >3 x institutional upper limit of normal) or renal disease (serum creatinine >2.0 mg/dL)

3. Participants with significant cardiovascular disease or stroke

4. Participants with history of seizures

5. Endocrine disease such as hypothyroidism or Cushing syndrome

6. History or existence of neurological or psychological disease (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, bulimia and so on)

7. Use of medication within the past 3 months that could have an effect on weight (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medication having an effect on absorption, metabolism and excretion).

8. A know history or present condition of allergic response to any pharmaceutical products and supplements.

9. History of weight reduction surgery, bariatric surgery and so on

10. Weight reduction > 10% within the past 6 months

11. Women in child bearing age unable to practice any form of contraception

12. Participants on herbal supplements/any other wellness product

13. History of alcohol, tobacco, substance or drug abuse

14. Subject who has participated in a clinical study within the last 30 days prior to entering this study.

15.Participants with hypersensitivity to any of the ingredients of the study products.

16. Refusing consent or physician uncomfortable with patient compliance to treatments or follow up.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Primary Measurement will be the safety and tolerability of iSlim flat tummies through, <br/ ><br>2.Laboratory Parameters Hematology, Biochemistry, liver profile, Kidney profile, Lipid Profile, Urine analysis, Fasting blood glucose, & ECG at Screening (-0 day) and end of the Study (90 day). <br/ ><br>Timepoint: Day 0 and Day 90
Secondary Outcome Measures
NameTimeMethod
1.Body Weight/BMI: The difference in mean percent loss of baseline body weight. OR, the proportion of subjects who lose at least 5 percent of baseline body weight. <br/ ><br>2.HbA1c Activity <br/ ><br>3.Blood Pressure <br/ ><br>4.Fasting Blood Glucose and Serum Insulin <br/ ><br>5.Lipid Profile <br/ ><br>6.Waist Circumference <br/ ><br>7.Inflammatory Biomarker: ESR & hsCRP <br/ ><br>8.Serum biomarkers: Leptin and Ediponectin <br/ ><br>9.Appetite measure: Simplified Nutritional Appetite Questionnaire (SNAQ) <br/ ><br>10.Subject Photographs (day 0 and day 90) <br/ ><br>Timepoint: Day 0,Day 45 and Day 90
© Copyright 2025. All Rights Reserved by MedPath